2c6c

File:2c6c.gif

spinqualitylabelsall models 2c6c, resolution 2.00Å Show:Asymmetric Unit Biological Assembly Drag the structure with the mouse to rotate   Export Animated Image

MEMBRANE-BOUND GLUTAMATE CARBOXYPEPTIDASE II (GCPII) IN COMPLEX WITH GPI-18431 (S)-2-(4-IODOBENZYLPHOSPHONOMETHYL)-PENTANEDIOIC ACID

OverviewOverview

Membrane-bound glutamate carboxypeptidase II (GCPII) is a zinc, metalloenzyme that catalyzes the hydrolysis of the neurotransmitter, N-acetyl-L-aspartyl-L-glutamate (NAAG) to N-acetyl-L-aspartate and, L-glutamate (which is itself a neurotransmitter). Potent and selective, GCPII inhibitors have been shown to decrease brain glutamate and provide, neuroprotection in preclinical models of stroke, amyotrophic lateral, sclerosis, and neuropathic pain. Here, we report crystal structures of the, extracellular part of GCPII in complex with both potent and weak, inhibitors and with glutamate, the product of the enzyme's hydrolysis, reaction, at 2.0, 2.4, and 2.2 A resolution, respectively. GCPII folds, into three domains: protease-like, apical, and C-terminal. All three, participate in substrate binding, with two of them directly involved in, C-terminal glutamate recognition. One of the carbohydrate moieties of the, enzyme is essential for homodimer formation of GCPII. The, three-dimensional structures presented here reveal an induced-fit, substrate-binding mode of this key enzyme and provide essential, information for the design of GCPII inhibitors useful in the treatment of, neuronal diseases and prostate cancer.

DiseaseDisease

Known diseases associated with this structure: Myocardial infarcation, susceptibility to OMIM:[602855]

About this StructureAbout this Structure

2C6C is a Single protein structure of sequence from Homo sapiens with NAG, ZN, CA, CL and 24I as ligands. Active as Glutamate carboxypeptidase II, with EC number 3.4.17.21 Structure known Active Site: AC1. Full crystallographic information is available from OCA.

ReferenceReference

Structure of glutamate carboxypeptidase II, a drug target in neuronal damage and prostate cancer., Mesters JR, Barinka C, Li W, Tsukamoto T, Majer P, Slusher BS, Konvalinka J, Hilgenfeld R, EMBO J. 2006 Mar 22;25(6):1375-84. Epub 2006 Feb 9. PMID:16467855

Page seeded by OCA on Mon Nov 12 21:11:32 2007